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Polyubiquitin (pUb) chains formed between the C terminus of
ubiquitin and lysine 63 (K63) or methionine 1 (M1) of another
ubiquitin have been implicated in the activation of the canonical
IκB kinase (IKK) complex. Here, we demonstrate that nearly all of
the M1-pUb chains formed in response to interleukin-1, or the Toll-
Like Receptors 1/2 agonist Pam3CSK4, are covalently attached to
K63-pUb chains either directly as K63-pUb/M1-pUb hybrids or in-
directly by attachment to the same protein. Interleukin-1 receptor
(IL-1R)-associated kinase (IRAK) 1 is modiﬁed ﬁrst by K63-pUb
chains to which M1-pUb linkages are added subsequently, and
myeloid differentiation primary response gene 88 (MyD88) and
IRAK4 are also modiﬁed by both K63-pUb and M1-pUb chains.
We show that the heme-oxidized IRP2 ubiquitin ligase 1 interact-
ing protein (HOIP) component of the linear ubiquitin assembly
complex catalyzes the formation of M1-pUb chains in response
to interleukin-1, that the formation of K63-pUb chains is a prereq-
uisite for the formation of M1-pUb chains, and that HOIP interacts
with K63-pUb but not M1-pUb linkages. These ﬁndings identify
K63-Ub oligomers as a major substrate of HOIP in cells where
the MyD88-dependent signaling network is activated. The TGF-
beta–activated kinase 1 (TAK1)-binding protein (TAB) 2 and TAB3
components of the TAK1 complex and the NFκB Essential Modiﬁer
(NEMO) component of the canonical IKK complex bind to K63-pUb
chains and M1-pUb chains, respectively. The formation of K63/M1-
pUb hybrids may therefore provide an elegant mechanism for
colocalizing both complexes to the same pUb chain, facilitating
the TAK1-catalyzed activation of IKKα and IKKβ. Our study may
help to resolve the debate about the relative importance of K63-
pUb and M1-pUb chains in activating the canonical IKK complex.
LUBAC | TNF Receptor-Associated Factor 6 | Ubc13 | NF-κB
Interleukin-1 (IL-1) or ligands that activate Toll-Like Receptors(TLRs) initiate “downstream” signaling events by recruiting
the adaptor protein MyD88 (1), IL-1 Receptor (IL-1R)-Associ-
ated Kinase 4 (IRAK4), IRAK1, and IRAK2 to form an oligo-
meric structure termed the Myddosome (2, 3). IRAKs 1 and 2
undergo covalent modiﬁcation by phosphorylation and
ubiquitylation and interact with the E3 ubiquitin ligase TNF
Receptor-Associated Factor 6 (TRAF6) (4). TRAF6 can com-
bine with the E2-conjugating complex Ubc13-Uev1a to generate
K63-pUb chains in vitro. These K63-Ub chains, not anchored to
any other protein, were reported to activate the TAK1 complex in
vitro (5–7), probably via conformational changes induced by an
interaction with the Npl40 Zinc Finger (NZF) domain of TAB2
and TAB3, which bind to K63-pUb chains speciﬁcally in vitro (8,
9). Once activated, TAK1 phosphorylates the canonical IκB ki-
nase (IKK) complex and the mitogen-activated protein (MAP)
kinase kinases that activate c-Jun N-terminal kinases (JNKs) and
p38 MAP kinases, which then trigger “downstream” signaling
events. The IL-1–stimulated activation of the canonical IKK com-
plex andMAP kinases fails to occur in mouse embryonic ﬁbroblasts
(MEFs) from TRAF6-deﬁcient mice (10) or TAK1-deﬁcient mice
(11) or in MEFs from mice that express an inactive, truncated
form of TAK1 (12). Moreover, wild-type TRAF6, but not an E3
ligase-deﬁcient mutant, restores IL-1 signaling to TRAF6-
deﬁcient MEFs (10). These observations support the hypothesis
that TRAF6-generated K63-pUb chains are required for the IL-1–
stimulated activation of TAK1 and that TAK1 expression is es-
sential to activate the IKK complex and MAP kinases in MEFs.
NFκB Essential Modiﬁer (NEMO), an integral component of
the canonical IKK complex, was reported to bind K63-pUb
chains (13, 14), and NF-κB–dependent gene transcription in-
duced by TNFα or IL-1 was restored to NEMO-deﬁcient MEFs
by the reintroduction of wild-type NEMO but not by the pUb-
binding–defective mutant NEMO[D311N] (13–15). Moreover,
the TNFα-stimulated degradation of IκBα and the TNFα or
IL-1–stimulated translocation of the p50/p65 NFκB subunits to
the nucleus was impaired in ﬁbroblasts from immune-deﬁcient
human patients expressing the NEMO[D311G] mutant. Thus,
the activation of the canonical IKK complex is attenuated in cells
expressing pUb-binding–defective mutants of NEMO (16).
More recently, NEMO was found to bind linear-Ub oligomers
with 100-fold higher afﬁnity than K63-Ub oligomers of equiva-
lent length (17, 18), suggesting that NEMO may bind linear-pUb
chains preferentially in vivo. These pUb chains, which are pro-
duced by the formation of a peptide bond between the α-amino
group of the N-terminal methionine (M) of one ubiquitin and
the C-terminal glycine of another ubiquitin, will be termed M1-
pUb chains hereafter. M1-Ub linkages can be generated in vitro
by the linear ubiquitin assembly complex (LUBAC) (19), which is
composed of three components: Heme-Oxidized IRP2 ubiquitin
Ligase 1 (HOIL-1), HOIL-1 interacting protein (HOIP), and
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Sharpin (20–22). Importantly, the IL-1–stimulated activation
of the canonical IKK complex was impaired in MEFs from
HOIL-1−/− mice (23), suggesting an important role for M1-pUb
chains in this process. Moreover, the readdition of LUBAC to
HeLa extracts depleted of this E3 ligase restored the activation
of the canonical IKK complex in vitro. Furthermore, LUBAC
was reported to activate NFκB-dependent gene transcription
when overexpressed in wild-type MEFs, but not in NEMO-
deﬁcient MEFs (24). It was inferred from these studies that
LUBAC-catalyzed M1-pUb chain formation, rather than K63-
pUb chain formation, was critical for the activation of the ca-
nonical IKK complex.
Here, we report that nearly all of the M1-pUb chains formed
when the MyD88 signaling network is activated are attached
covalently to K63-pUb chains. We further show that the IL-1–
stimulated formation of K63-pUb chains is a prerequisite for the
formation of M1-pUb chains and that HOIP binds speciﬁcally to
K63-pUb chains in vitro. We suggest that the formation of K63-
pUb/M1-pUb hybrids permits the recruitment of TAK1 and the
canonical IKK complex to the same pUb chains, facilitating the
TAK1-catalyzed phosphorylation and activation of the IKKs.
Results
IL-1 Stimulates the Formation of M1-pUb and K63-pUb Chains in IL-1
Receptor Cells. HEK293 cells stably expressing the IL-1 receptor
(termed here IL-1R cells) (25) were stimulated with IL-1, and
the pUb chains captured from the cell extracts on immobilized
Halo-NEMO were analyzed. The Halo-NEMO beads captured
M1-pUb and K63-pUb chains from the extracts of IL-1–stimu-
lated cells (Fig. S1A), but did not capture K48-pUb chains or
K11-pUb chains, in contrast to Halo–tandem-repeated ubiquitin-
binding entities (TUBEs) (26), which captured these types of
pUb chain (Fig. S1B). M1-pUb or K63-pUb chains captured by
NEMO were not detectable in the absence of IL-1 stimulation,
but could be detected within 2 min of exposure to IL-1, the
amounts peaking after 10–15 min and declining thereafter (Fig.
1A). The formation of these pUb chains paralleled the phos-
phorylation of p105, an authenticated physiological substrate of
IKKβ (27, 28), whereas the phosphorylation (activation) of JNK
and p38α MAPK peaked slightly later (Fig. 1A). The NEMO
[D311N] mutant did not capture any pUb chains (Fig. S1A).
M1-pUb Chains Captured by NEMO Are Linked to K63-pUb Chains.
Otulin is a deubiquitylase that hydrolyzes M1-pUb chains spe-
ciﬁcally (29, 30) (Fig. S2A), whereas AMSH-LP cleaves K63-pUb
chains speciﬁcally (Fig. S2B) (9). As expected, Otulin hydrolyzed
nearly all of the M1-pUb chains captured from the cell extracts
by immobilized NEMO (Fig. 1B, P1, lanes 5 and 6). However,
unexpectedly, Otulin treatment reduced the size of the large
K63-pUb chains (Fig. 1B, P2; compare lanes 5 and 6 with lanes
3 and 4) and generated a variety of faster-migrating, small pUb
oligomers (Fig. 1B, P3, lanes 5 and 6) that comigrated with K63-
pUb chains (Fig. 1C, lanes 5–8) and were hydrolyzed by AMSH-LP
(Fig. 1B, P3; compare lanes 9 and 10 with lanes 5 and 6). The
generation of these small K63-Ub oligomers explains why the
amount of the larger K63-pUb chains was reduced after Otulin
treatment. Conversely, treatment with AMSH-LP hydrolyzed all
of the K63-pUb chains captured by NEMO (Fig. 1B, P2, lanes
7 and 8) and increased the formation of faster-migrating small
Ub oligomers (Fig. 1B, P3, lanes 7 and 8) that comigrated with
M1-pUb chains (Fig. 1C, lanes 1–4) and could be hydrolyzed by
Otulin (Fig. 1B, P3; compare lanes 9 and 10 with 7 and 8). The
reduced size of the large pUb chains after incubation with either
Otulin or AMSH-LP could be explained if the M1-pUb chains
and K63-pUb chains were attached covalently to different lysine
residues on the same protein or if the M1-pUb chains were at-
tached directly to K63-pUb chains as K63-pUb/M1-pUb “hybrid”
molecules. However, the generation of small K63-Ub oligomers
after incubation with Otulin and small M1-Ub oligomers after
incubation with AMSH-LP, which are not attached to any other
protein, is compatible only with K63/M1-pUb hybrid formation.
Polyubiquitin Chains Attached to IRAK1 and Captured by NEMO Are
K63-pUb/M1-pUb Hybrids. We identiﬁed many proteins by mass
spectrometry that were captured by Halo-NEMO from the extracts
of IL-1–stimulated IL-1R cells in a ubiquitin-dependent manner
because they were not captured by the NEMO[D311N] mutant.
Those proteins of relevance to the present study are listed in
Table S1. They include many of the proteins known to participate
in the MyD88-signaling network (Introduction), namely MyD88
itself, IRAK1, IRAK4, TRAF6, the HOIP, HOIL-1 and Sharpin
components of LUBAC and the TAB1, TAB2, TAB3 and TAK1
components of the TAK1 complex (Tables S1 and S2). Proteins
captured by Halo-NEMO in a ubiquitin-independent manner
Fig. 1. IL-1 induces the formation of K63-pUb/M1-pUb
hybrids. (A) IL-1R cells were stimulated for 10 min with 5 ng/
mL IL-1β and lysed with 100 mM iodoacetamide to inhibit
deubiquitylases, and the pUb chains and associated proteins
were captured from the cell extracts with Halo-NEMO. The
captured proteins were identiﬁed by immunoblotting with
antibodies that recognize K63-pUb or M1-pUb chains spe-
ciﬁcally (Top two subpanels). The extracts (25 μg protein)
were immunoblotted with the antibodies indicated (Bottom
four subpanels). (B) As in A, except that the pUb chains
captured by Halo-NEMO were incubated in the absence
(control) or presence of Otulin, AMSH-LP or both deubi-
quitylases before SDS/PAGE and immunoblotting with
antibodies that recognize M1-pUb chains (P1), K63-pUb
chains (P2), or with an antibody that recognizes M1-pUb
and K63-pUb chains equally well (P3). In P3, the lower half
of the membrane was developed for 10 times longer than
the upper half. (C) Authentic M1-pUb oligomers (30 ng, lane
1; 10 ng, lane 2) and K63-Ub oligomers (3 ng, lane 7 and 6
ng, lane 8) were used as markers to demonstrate that the
small Ub oligomers formed in B after treatment with AMSH-
LP were linked via M1 of ubiquitin (lanes 3 and 4) and that
those formed by treatment with Otulin (lanes 5 and 6) were
linked via K63.
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included, as expected, IKKα and IKKβ (Table S3), the other
components of the canonical IKK complex.
We found that IRAK1 became covalently modiﬁed by pUb
chains in response to IL-1, explaining why it was captured by
Halo-NEMO. Incubation with Otulin reduced the size of the
pUb chains attached to IRAK1 (Fig. 2A, Upper, lanes 6 and 7),
and these Ub chains could now be hydrolyzed by AMSH-LP,
indicating that they were linked via K63 of ubiquitin (Fig. 2A,
Upper, lanes 8 and 9). Importantly, none of the IRAK1 was
reconverted to either the monoubiquitylated or unmodiﬁed forms
of the protein after incubation with Otulin (Fig. 2A, Upper;
compare lanes 6 and 7 with lanes 2 and 3) even though Otulin
hydrolyzed virtually all of the M1-Ub linkages captured by
NEMO (Fig. 1B, P1, lanes 5 and 6). These results are not
compatible with the M1-pUb chains and K63-pUb chains being
attached to different lysine residues in IRAK1. They are also not
compatible with IRAK1 being modiﬁed initially with M1-Ub
linkages and subsequently with K63-Ub linkages. The experi-
ments therefore suggested that IRAK1 was modiﬁed by K63-
pUb chains initially, to which M1-pUb chains were attached
subsequently. These results were not speciﬁc to this agonist or
cell type because similar results were obtained in human THP1
monocytes stimulated with Pam3CSK4, an activator of the TLR1/2
heterodimer that also signals via MyD88 (Fig. 2A, Lower).
Topology of the pUb Chains Attached to MyD88 and IRAK4. A sig-
niﬁcant proportion of the MyD88 and IRAK4 captured by Halo-
NEMO from the extracts of IL-1–stimulated IL-1R cells (Fig.
2B) or Pam3Csk4-stimulated THP1 monocytes (Fig. S3A) un-
derwent polyubiquitylation. Similar to IRAK1, treatment with
Otulin or AMSH-LP reduced the size of the large pUb chains
attached to MyD88 and IRAK4 (Fig. 2B; compare lanes 4–7 with
lanes 2 and 3), whereas treatment with Otulin plus AMSH-LP
converted MyD88 and IRAK4 to monoubiquitylated and un-
modiﬁed species. The pUb chains attached to MyD88 and IRAK4
therefore also contain both K63-Ub and M1-Ub linkages. How-
ever, in contrast to IRAK1, incubation with Otulin generated some
monoubiquitylated MyD88 and IRAK4, suggesting that some of
the M1-pUb chains may be attached to these proteins without their
prior modiﬁcation by K63-pUb chains.
Like the nonspeciﬁc deubiquitylase USP2 (Fig. 2 A and B, lanes
10 and 11), AMSH-LP not only hydrolyzed K63-pUb chains but
also partially reconverted IRAK1 and MyD88, and largely
reconverted IRAK4, to the unmodiﬁed species (Fig. 2 A and B;
compare lanes 4 and 5 with lanes 2 and 3). This indicates that
AMSH-LP can cleave the isopeptide bond(s) formed between the
C terminus of the ﬁrst ubiquitin and the e-amino moiety of a lysine
residue(s) on these proteins. However, in the case of IRAK1 and
MyD88, this isopeptide bond is hydrolyzed more slowly than K63-
Ub linkages by AMSH-LP because increased formation of the
monoubiquitylated species is also observed.
Polyubiquitylation of Other Proteins. The ubiquitylated TRAF6
formed in response to IL-1 was not modiﬁed by M1-pUb chains
because incubation with Otulin had no effect (Fig. S3B). The
ubiquitylated forms of TRAF6 detected after treatment with
AMSH-LP plus Otulin may arise from monoubiquitylation of
several lysine residues on TRAF6.
Minor amounts of HOIP and HOIL-1 were converted to
slower-migrating forms in response to IL-1, which disappeared
after USP2 treatment, indicating that they were ubiquitylated
species (Fig. S3C). Sharpin was partially converted to a USP2-
sensitive monoubiquitylated form in response to IL-1 (Fig. S3C).
A small amount of the endogenous NEMO was also converted to
a monoubiquitylated form in IL-1–stimulated IL-1R cells (Fig.
S3D). Trace amounts of polyubiquitylated NEMO were also
Fig. 2. Characterization of polyubiquitin chains
attached covalently to proteins captured by Halo-
NEMO from the extracts of IL-1R cells and THP1
monocytes. (A) IL-1R cells were stimulated with 5 ng/mL
IL-1β (Upper) or THP1 monocytes with 1 μg/mL
Pam3CSK4 (Lower) and the experiment was then
performed as in Fig. 1B, except that the proteins
captured by Halo-NEMO were treated for 1 h with
λPPase (to dephosphorylate IRAK1) in the absence
(control) or presence of the deubiquitylases AMSH-LP,
Otulin, AMSH-LP plus Otulin, or USP2. The samples
were then subjected to SDS/PAGE and immunoblotted
for IRAK1. (B) As in A, except that λPPase was omitted
and the PVDF membranes were immunoblotted with
antibodies that recognize MyD88 and IRAK4. mUb,
monoubiquitylated.
Fig. 3. Two distinct forms of pUb-IRAK1 identiﬁed by the
combined use of Halo-NEMO and Halo-TAB2. (A) The ex-
periment was carried out as in Fig. 2A except that pUb chains
and associated proteins were captured with Halo-NEMO or
Halo-TAB2 [ﬁrst pull-down (PD)]. Where indicated, the
supernatants from the ﬁrst PD were subjected to a second PD
using either Halo-NEMO or Halo-TAB2 as indicated. Captured
pUb chains or IRAK1 were identiﬁed by immunoblotting. (B)
As in A, except that proteins that were captured by Halo-NEMO
or Halo-TAB2 from the supernatant of the ﬁrst Halo-NEMO pull-
down, were incubated with Otulin. The ubiquitylation of IRAK1
was then analyzed by immunoblotting with a speciﬁc antibody.
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detected, which were hydrolyzed by AMSH-LP but not by Otulin
(Fig. S3D; compare lanes 3–8), indicating that NEMO is not
modiﬁed signiﬁcantly with M1-Ub chains after IL-1 stimulation.
Sequential Capture of pUb Chains by Halo-TAB2 and Halo-NEMO. The
Npl4 Zinc Finger (NZF) domain of the TAB2 component of the
TAK1 complex binds speciﬁcally to K63-pUb chains (8, 9).
However, we found that a tandem repeat of the NZF of TAB2
(termed here Halo-TAB2) also captured all of the large M1-pUb
chains present in the extracts of IL-1–stimulated cells (Fig. 3A)
because no high-molecular-mass M1-pUb chains were captured
by Halo-NEMO from the supernatant obtained after the ﬁrst
Halo-TAB2 pull-down (Fig. 3A, P1; compare lanes 4 and 12).
Conversely, no M1-pUb chains were captured from the super-
natant of the ﬁrst Halo-NEMO pull-down by Halo-TAB2 (Fig.
3A, P1; compare lanes 2 and 8). Thus, both Halo-TAB2 and
Halo-NEMO deplete the cell extracts of M1-pUb chains. On the
other hand, Halo-TAB2 captured K63-pUb chains (Fig. 3A, P2,
lanes 7 and 8) and more pUb-IRAK1 (Fig. 3A, P3, lane 8) from
the supernatant of the ﬁrst Halo-NEMO pull-down, whereas
Halo-NEMO did not (Fig. 3A, P2 and P3, lanes 5 and 6). The
size of pUb-IRAK1 captured by Halo-TAB2 from the superna-
tant of the ﬁrst NEMO pull-down was smaller than that captured
by Halo-NEMO (Fig. 3B; compare lanes 5 and 6 with 1 and 2).
Moreover, unlike the pUb-IRAK1 captured by NEMO (Fig. 3B;
compare lanes 7 and 8 with 1 and 2), the pUb-IRAK1 was not
reduced in size by treatment with Otulin (Fig. 3B; compare lanes
5 and 6 with 9 and 10). Thus, IL-1 stimulation generates two
forms of pUb-IRAK1, one linked to K63/M1-pUb hybrids
(captured by Halo-NEMO or Halo-TAB2) and the other linked
only to K63-pUb chains (captured by Halo-TAB2 from the
supernatant of the ﬁrst NEMO pull-down).
In contrast to Halo-NEMO, Halo-TAB2 captured K63-pUb
chains from the extracts of cells not stimulated with IL-1 (Fig. 3A,
P2; compare lanes 1 and 3). Taken together, these results establish
that NEMO captures M1-pUb chains selectively from the cell
extracts, whereas Halo-TAB2 captures only K63-pUb chains.
However, both Halo-tagged proteins deplete M1-pUb chains from
the extracts of IL-1–stimulated cells because virtually all of the
M1-pUb chains are attached covalently to K63-pUb chains.
LUBAC Is the Only E3 Ubiquitin Ligase That Catalyzes the Formation of
M1-pUb Chains in IL-1–Stimulated Mouse Embryonic Fibroblasts. Al-
though LUBAC catalyzes the formation of M1-pUb chains in
vitro, it is not established that it is the only E3 ubiquitin ligase that
generates these chains in vivo. We therefore generated knock-in
mice in which HOIP was replaced by the E3 ligase-inactive HOIP
[C879S] mutant, in which the catalytic cysteine was replaced by
serine (Fig. S4A). The human HOIP[C885S] mutant, equivalent to
Cys879 of murine HOIP, had no detectable E3 ligase activity (Fig.
S4B). The HOIP[C879S] mice displayed embryonic lethality, no
embryos being detectable from E11 onward; ﬁbroblasts from
mouse embryos that were 10.5 d old (MEFs) were therefore used
for all subsequent studies. IL-1 did not induce detectable M1-pUb
chain formation in HOIP[C879S] MEFs (Fig. 4A), establishing
that HOIP is the catalytic subunit of LUBAC and the only E3
ligase that can produce M1-pUb chains in IL-1–stimulated MEFs.
The expression of HOIP, HOIL-1, and Sharpin was similar in
MEFs from HOIP[C879S] and wild-type mice (Fig. 4A).
The IL-1–stimulated activation of IKKβ was reduced in
MEFs from the HOIP[C879S] mice, as judged by reduced
Fig. 4. Studies on the activity, pUb-binding prop-
erties, and role of LUBAC. (A) MEFs from mice
expressing either wild-type (wt) HOIP or the HOIP
[C879S] mutant were stimulated with 5 ng/mL IL-1α
for the times indicated. M1-pUb chains captured
from the cell extracts with Halo-NEMO were iden-
tiﬁed by immunoblotting with a speciﬁc antibody
(Top). Cell extracts (20 μg protein) were immuno-
blotted with the antibodies indicated (Bottom
seven subpanels). (B) IL-1R cells stably expressing
shRNAs speciﬁc for HOIP and HOIL-1, or an empty
control vector, were stimulated with 5 ng/mL IL-1β
and pUb chains captured from extracts with Halo-
NEMO or Halo-TAB2. The captured M1-pUb (Top)
and K63-pUb chains (Top, second subpanel) were
identiﬁed by immunoblotting with speciﬁc anti-
bodies. Aliquots of the extracts (20 μg protein) were
also immunoblotted with the antibodies indicated
(Bottom four subpanels). (C) IL-1R cells were not
stimulated or stimulated for 15 min with 5 ng/mL
IL-1β. The cells were lysed without iodoacetamide to
prevent the inactivation of LUBAC, which was then
immunoprecipitated from the extracts with anti–
HOIL-1, anti-Sharpin, or anti-HOIP. The M1-pUb
chains formed after 60 min by LUBAC were exam-
ined by immunoblotting. The immunoprecipitates
were also immunoblotted for HOIP, HOIL-1, and
Sharpin. (D) Full-length GST-HOIP and GST-HOIL-1
were mixed with K63-Ub or M1-Ub oligomers, and,
after capture on glutathione-Sepharose, the pUb-
oligomers bound to each protein were analyzed by
immunoblotting with anti-ubiquitin. Lanes 1 and
6 show, respectively, the K63-pUb oligomers and
M1-pUb oligomers used. Lanes 2–5 show the K63-pUb
chains and lanes 7–10 the M1-pUb chains captured by
each protein.
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phosphorylation of p105, a well-authenticated physiological
substrate of IKKβ (27, 28). Thus, M1-pUb chain formation was
required for optimal activation of the canonical IKK complex. In
contrast, the IL-1–stimulated activation of JNK and p38α MAP
kinase was enhanced in HOIP[C879S] MEFs, demonstrating that
M1-pUb chain formation is not required for the activation of
these protein kinases (Fig. 4A).
The knock-down of both HOIP and HOIL-1 also reduced the
IL-1–stimulated formation of M1-pUb chains and the phos-
phorylation of p105 in IL-1R cells, without affecting the IL-1–
stimulated formation of K63-pUb chains signiﬁcantly (Fig. 4B).
LUBAC Is Active in Unstimulated Cells. Because M1-pUb chains were
formed only in response to IL-1 in IL-1R cells or to Pam3CSK4 in
THP1 cells, we anticipated that LUBAC would be activated by
these agonists. However, unexpectedly, LUBAC immunoprecipi-
tated from IL-1R cell extracts with anti-HOIP was already active
in serum grown cells not stimulated with IL-1, and activity did not
increase in response to IL-1 (Fig. 4C and Fig. S5 A and B). Similar
results were obtained in Pam3CSK4-stimulated THP1 cells. It
was possible that HOIP had been activated by interaction with
the anti-HOIP antibody, but the same results were obtained if
LUBAC was immunoprecipitated from the cell extracts with
anti–HOIL-1 or anti-Sharpin (Fig. 4C). It is unlikely that anti-
bodies raised against all three components of LUBAC would
activate its E3 ligase activity. We therefore conclude that
LUBAC does not undergo a stable covalent modiﬁcation in re-
sponse to IL-1 that converts it from an inactive to an active form.
The antibodies raised against any one component of LUBAC
immunoprecipitated the others, conﬁrming that, as in other cells
(31, 32), LUBAC is a hetero-trimeric complex composed of
HOIP, HOIL-1, and Sharpin, a complex remaining intact after
IL-1 stimulation (Fig. 4C, Lower).
Formation of M1-pUb Chains Requires the Formation of K63-pUb
Chains. The E2-conjugating complex Ubc13-Uev1a directs the
formation of K63-pUb chains in cells. To investigate whether the
formation of M1-pUb chains was affected by the formation of
K63-pUb chains, we generated IL-1R cells deﬁcient in Ubc13
(Fig. 5). As expected, the IL-1–stimulated formation of K63-pUb
chains was almost abolished (Fig. 5, Top) but, interestingly, the
IL-1–stimulated formation of M1-pUb chains was also greatly
reduced (Fig. 5, Top, second subpanel). Control experiments
showed that the expression of HOIP, HOIL-1, and Sharpin was
unaltered in the Ubc13-deﬁcient cells (Fig. 5). The phosphory-
lation of IKKβ, its substrate p105, and JNK was also impaired in
the Ubc13-deﬁcient cells (Fig. 5). Importantly, the reexpression
of Ubc13 restored the IL-1–stimulated formation of K63-pUb
and M1-pUb chains and the activation of the canonical IKK
complex and MAP kinases (Fig. S5C). Taken together, these
experiments establish that the formation of M1-pUb chains in
IL-1R cells requires K63-pUb chain formation.
HOIP Interacts with K63-pUb Chains but Not with M1-pUb Chains.
Because most of the M1-pUb chains were attached covalently
to K63-pUb chains, this indicated that K63-pUb oligomers were
a major substrate for LUBAC in IL-1–stimulated cells. An
N-terminal fragment of HOIP containing its two NZF domains
was reported to bind weakly to K48-Ub andM1-Ub oligomers but
more strongly to K63-Ub oligomers (33). Here, we found that
full-length HOIP captured K63-Ub oligomers (Fig. 4D, lanes 2
and 3), but not M1-Ub oligomers (Fig. 4D, lanes 7 and 8) under
the experimental conditions that we used. The NZF of HOIL-1
was reported to interact with M1-Ub dimers (34). We conﬁrmed
this ﬁnding using full-length HOIL-1 (Fig. 4D, lanes 9 and 10),
but also detected weak binding to K63-Ub oligomers (Fig. 4D,
lanes 4 and 5). Interestingly, HOIP and HOIL-1 captured longer
K63-Ub oligomers preferentially, even though they were minor
components in the preparation of mixed K63-Ub oligomers used
for these binding studies (Fig. 4D, lane 1). The NZF of Sharpin
was reported to interact with M1-Ub and K63-Ub oligomers (20,
22). However, full-length Sharpin failed to interact with M1-Ub,
K63-Ub, or K48-Ub oligomers under our experimental con-
ditions, indicating that the binding of Ub oligomers to Sharpin is
much weaker than to HOIP or HOIL-1.
Discussion
In this paper we show that most of the M1-pUb chains formed in
IL-1–stimulated IL-1R cells or Pam3CSK4-stimulated THP1
monocytes, are attached covalently to K63-pUb chains and that
signiﬁcant formation of M1-pUb linkages cannot take place until
K63-pUb chains are produced (Fig. 5 and Fig. S5C). Our ﬁnding
that HOIP interacts speciﬁcally with K63-pUb chains may help
to explain why the formation of M1-pUb chains depends on the
prior formation of K63-pUb chains (Fig. 4D). However, it cannot
be the only reason because substantial amounts of K63-pUb
chains were present in serum grown cells not stimulated with
IL-1 (Fig. 3A), and yet M1-pUb chains did not accumulate under
these conditions, despite LUBAC being active under these
conditions. We were also unable to accelerate the LUBAC-
Fig. 5. Formation of M1-pUb chains is dependent on the prior formation of
K63-pUb chains. IL-1R cells stably expressing shRNA speciﬁc for Ubc13 or an
empty vector were stimulated for the times indicated with 5 ng/mL IL-1β,
and the cells were lysed in the presence of 100 mM iodoacetamide. The pUb
chains captured from the cell extracts with Halo-NEMO were subjected to
SDS/PAGE and immunoblotting with antibodies that recognize K63-pUb
chains (Top) or M1-pUb chains (Top, second subpanel). The cell extracts
(20 μg protein) were also subjected to SDS/PAGE and immunoblotted with
the antibodies indicated (Bottom eight subpanels).
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Fig. 6. Enhanced activation of the canonical IKK complex via the MyD88-
dependent formation of K63/M1-linked hybrid ubiquitin chains. The ﬁgure
shows schematically how the formation of K63/M1-pUb hybrids may permit
the corecruitment of the TAK1 and canonical IKK complexes via the in-
teraction of TAB2/3 with K63-pUb chains and NEMO with M1-pUb chains,
thereby facilitating the activation of IKKα and IKKβ by TAK1.
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catalyzed formation of M1-pUb chains in vitro by adding K63-
Ub oligomers to the assays. The recruitment of LUBAC to a
MyD88-dependent signaling complex containing the K63-pUb
chain-generating E3 ligase TRAF6, and perhaps other K63-pUb
chain-generating E3 ligases, would therefore seem to be needed
before the M1-pUb chains generated by LUBAC can accumulate
and be coupled to K63-pUb chains. Perhaps the interaction of
K63-pUb/M1-Ub linkages with one or more proteins in this
complex decreases the rate at which they are hydrolyzed by
Otulin and/or other deubiquitylases in cells. Alternatively, or in
addition, one or more M1-pUb hydrolase(s) may be converted to
less active forms when the MyD88-signaling network is activated.
The topology of the K63-pUb/M1-pUb hybrids is clearly het-
erogeneous because the AMSH-LP–catalyzed hydrolysis of K63-
pUb chains or the Otulin-catalyzed hydrolysis of M1-pUb chains
generated K63-Ub or M1-Ub oligomers, respectively, of varying
length (Fig. 1B and Fig. S6). Working out the precise topology of
these hybrid pUb chains will be a challenging project.
It was suggested that the activation of the TAK1 complex
results from a conformational change induced by the interaction
of K63-pUb chains with its TAB2 and TAB3 subunits (6, 7). In
contrast, NEMO binds 100-fold more tightly to M1-Ub dimers
than to K63-Ub dimers (17, 18) and captures M1-pUb chains
speciﬁcally from the extracts of IL-1–stimulated cells (Fig. 3).
The formation of K63-pUb/M1-pUb hybrids would therefore
appear to be a simple device for colocalizing TAK1 and the ca-
nonical IKK complex to the same pUb chain, facilitating the
TAK1-catalyzed activation of IKKα and IKKβ (Fig. 6). The
failure to form M1-pUb linkages in MEFs from HOIP[C879S]
knock-in mice (Fig. 4A), and hence K63-pUb/M1-pUb hybrids,
may not only reduce the activation of the canonical IKK complex
by preventing colocalization with TAK1, but also divert these
TAK1 molecules to the activation of MAP kinase kinases,
explaining why the IL-1–stimulated activation of JNK and p38α
MAP kinase was enhanced in MEFs from the HOIP[C879S]
knock-in mice (Fig. 4A). An enhanced activation of JNK was also
reported in MEFs from HOIL-1–deﬁcient mice, in which the
expression of HOIP was also reduced drastically (23).
It will clearly be of great interest to investigate whether the
formation of K63-pUb/M1-pUb hybrids is of more general sig-
niﬁcance and whether they participate in the regulation of other
biological processes dependent on K63-pUb chain formation,
such as the cellular response to DNA damage (35).
Materials and Methods
NEMO, the ubiquitin binding-defective mutant NEMO[D311N], a protein
expressing two copies of the NZF domain of TAB2, and TUBEs (26) were
expressed in Escherichia coli as Halo-tagged proteins. The bacteria were har-
vested; lysed in 50mMTris·HCl, pH 7.5, 150mMNaCl, 1 mMEGTA, 1 mMEDTA,
0.1% (vol/vol) 2-mercaptoethanol, 1 mM benzamidine, and 0.2 mM phenyl-
methylsulfonyl ﬂuoride (PMSF); and sonicated. The bacterial cell lysate was
centrifuged to removedebris, and the supernatantwas coupled to theHaloLink
resin (Promega) by incubation for 5 h at 4 °C as described by the manufacturer.
The resin was washed extensively with 50 mM Tris·HCl, pH 7.5, 0.5 M NaCl, 0.1
mM EDTA, 270 mM sucrose, 0.03% (wt/vol) Brij 35, 0.1% (vol/vol) 2-mercap-
toethanol, 0.2 mM PMSF, and 1 mM benzamidine and stored at 4 °C. To check
coupling efﬁciency, an aliquot of the resin was resuspended in 50 mM Tris·HCl,
pH 8.0, 150 mM NaCl, 0.5 mM EDTA, 1 mM DTT containing 0.1 μg/μL TEV pro-
tease to release covalently bound NEMO, NEMO[D311N], and the NZF domains
of TAB2 or TUBEs followed by SDS/PAGE and staining with Coomassie Blue. All
experimental procedures are described in SI Materials and Methods.
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